Quick Takeaways
- INCYTE CORP filed SCHEDULE 13G for Prelude Therapeutics, Inc. Common Stock, par value $0.0001 per share (PRLD).
- Disclosed ownership: 9.9%.
- Date of event: 03 Nov 2025.
INCYTE CORP - 03 Nov 2025 SCHEDULE 13G Report for Prelude Therapeutics, Inc. Common Stock, par value $0.0001 per share (PRLD)
- Filing Manager
- INCYTE CORP
- Reporting Manager
- INCYTE CORP
- Symbol
- PRLD
- Shares outstanding
- 44,162,869 shares
- Disclosed Ownership
- 4,372,124 shares
- Ownership
- 9.9%
- Form type
- SCHEDULE 13G
- Filing time
- 07 Nov 2025, 16:01:48 UTC
- Date of event
- 03 Nov 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"INCYTE CORP disclosed 9.9% ownership in Prelude Therapeutics, Inc. Common Stock, par value $0.0001 per share (PRLD) on 03 Nov 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 07 Nov 2025, 16:01.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| INCYTE CORP | 9.9% | 4,372,124 | 4,372,124 | 0 | /s/ Sheila A. Denton | Sheila A. Denton / Executive Vice President and General Counsel |